Management of the thrombotic lesion

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Brian C. Bigelow, M.D., Sudarshan Srivats, M.D., M.P.H.[2]

PCI in the Patient with Angiographically Visible Thrombus

Overview

Angiographically visible intracoronary thrombus predicts distal embolization, no-reflow/slow-flow, larger infarct size, microvascular obstruction (MVO), and excess mortality despite a patent epicardial vessel. High thrombus burden is generally defined as TIMI thrombus grade ≥3. The central management shift over the past decade is a reversal of legacy teaching: routine mechanical thrombus removal is no longer recommended. Strategies once assumed to reduce embolization—routine aspiration thrombectomy, routine distal protection in native vessels, and routine GP IIb/IIIa use—have failed to improve hard outcomes in randomized trials, and thrombectomy causes net harm through excess stroke. The modern approach prioritizes upstream and periprocedural antithrombotic pharmacotherapy, direct stenting where feasible, and selective (bailout) adjunctive thrombus-reduction reserved for large residual thrombus burden or established no-reflow.

This microchapter covers periprocedural management of angiographically visible thrombus, principally in the ST-elevation MI culprit lesion but also in NSTE-ACS and degenerated saphenous vein grafts (SVG). Thrombus grading and mechanisms of distal embolization/MVO are covered in adjacent microchapters.

Differentiating Thrombus from Mimics

Confirm the finding is thrombus before treating:

  • Coronary spasm produces focal narrowing responsive to intracoronary vasodilators.
  • Dissection produces a hazy/linear lucency treated with stenting rather than antithrombotic escalation.
  • Intracoronary imaging (OCT/IVUS) is increasingly used to resolve ambiguity in native vessels.

Aspiration Thrombectomy — Not Routine (Class 3: No Benefit)

Both the 2025 ACC/AHA/ACEP/SCAI ACS guideline and the 2021 ACC/AHA/SCAI revascularization guideline give a Class 3 (No Benefit), LOE A recommendation against routine manual aspiration thrombectomy before primary PCI in STEMI.[1][2] The 2023 ESC ACS guideline concurs.[3]

  • Trial basis: After the small single-center TAPAS trial suggested benefit, the larger TASTE and TOTAL trials showed no clinical benefit. In an individual-patient meta-analysis of over 18,000 patients, thrombectomy did not reduce cardiovascular death, reinfarction, stent thrombosis, TVR, or heart failure.[4]
  • Safety signal: In TOTAL, thrombectomy roughly doubled the rate of stroke, a difference apparent within 48 h and persisting to 1 year; procedural stroke carried high short-term mortality.[5][6]
  • High thrombus burden subgroup: In the TOTAL high-thrombus-burden subanalysis, thrombectomy did not significantly reduce cardiovascular death but did increase stroke; the pooled meta-analysis showed a similar pattern with non-significant interaction, so any selective benefit remains hypothesis-generating.[7][4]
  • NSTE-ACS: In NSTE-ACS with thrombus-containing lesions, adjunctive aspiration did not reduce MVO or MACE.[3]
  • Bailout role: Manual aspiration remains reasonable as bailout to remove thrombus persisting after wiring/ballooning or stenting, particularly with concomitant no-reflow. ESC states that after opening the vessel with a guide wire or balloon, aspiration "may be considered" for large residual thrombus.[3]
  • Rheolytic thrombectomy (AngioJet) showed no benefit and signals of harm (larger infarcts, higher mortality in AIMI) and is not supported for routine STEMI use.[2]

Direct Stenting

Direct stenting without predilation is a reasonable technique to minimize plaque/thrombus displacement and distal embolization when the lesion can be crossed and adequately visualized. It has not been shown to change hard outcomes and should not be forced when lesion preparation or sizing is uncertain.[8] This is a pragmatic, low-cost strategy rather than a guideline-mandated one.

Deferred Stenting — Not Routine

Delaying stent implantation to allow thrombus resolution under intensive antithrombotic therapy improves angiographic surrogates but not clinical outcomes. DEFER-STEMI reduced no-/slow-reflow and improved myocardial salvage.[9] However, the larger DANAMI-3-DEFER trial (deferral ~48 h) showed no improvement in death/HF/reinfarction/repeat revascularization, and its CMR substudy found no reduction in infarct size or MVO.[8][10] A meta-analysis confirmed improved reflow surrogates without mortality or reinfarction benefit.[11] Deferred stenting is therefore not recommended routinely; it may occasionally be individualized (e.g., very large thrombus with stable flow, or uncertain vessel sizing), balanced against reocclusion risk.

Adjunctive Pharmacotherapy

Upstream aspirin plus a potent P2Y12 inhibitor (ticagrelor or prasugrel) is the pharmacologic foundation; detailed loading and dosing are covered in the antithrombotic-therapy microchapter.

GP IIb/IIIa Inhibitors (Selective/Bailout)

In ACS undergoing PCI with large thrombus burden, no-reflow, or slow flow, adjunctive IV or intracoronary GP IIb/IIIa inhibitor is reasonable (Class 2a, LOE C-LD) to improve procedural success and reduce infarct size. Routine administration in ACS is discouraged—Class 3: Harm, LOE B-R in the 2025 ACS guideline—due to lack of ischemic benefit and increased bleeding in the potent-P2Y12/DES era; this is an escalation from the 2021 revascularization guideline, which graded routine use "3: No Benefit, LOE B-R." Intracoronary and intravenous administration have shown generally similar outcomes, so the intracoronary route has no established clinical superiority.[1][2] Agents: abciximab, eptifibatide, tirofiban.

Intracoronary Fibrinolytics (Uncertain/Not Supported)

Low-dose adjunctive intracoronary alteplase was tested in T-TIME (10 or 20 mg vs placebo after reperfusion, before stenting) and did not reduce MVO. A prespecified analysis found alteplase increased MVO and myocardial hemorrhage in patients with ischemic time ≥4 h, arguing against this approach in later presenters.[12][13] The dedicated STRIVE RCT tested intracoronary low-dose alteplase specifically in STEMI with large thrombus burden and was negative—alteplase was not superior to placebo for the composite of 30-day MACE, poor myocardial blush, distal embolization, or failed ST-resolution—and the authors state the data do not support routine use.[14] A 2026 meta-analysis did report lower MACE and improved reperfusion markers without excess major bleeding, so the pooled signal is conflicting; on balance, intracoronary lytics remain investigational/off-label rather than guideline-endorsed.[15]

Antithrombin Therapy

Unfractionated heparin remains the standard procedural anticoagulant; bivalirudin is an alternative and is preferred in heparin-induced thrombocytopenia. Fondaparinux should not be used as sole anticoagulant in primary PCI due to catheter thrombosis risk. Detailed dosing belongs to the antithrombotic-therapy microchapters.

Distal Embolic Protection

  • Native coronary STEMI: Not effective—neither occlusion/aspiration (PercuSurge, EMERALD) nor filter devices (PROMISE) improved outcomes; not recommended.
  • SVG PCI: Embolic protection is reasonable when technically feasible (Class 2a, LOE B-R) to reduce distal embolization, a downgrade from the older Class I recommendation (ESC likewise downgraded to Class IIa). Evidence rests largely on the single SAFER trial (GuardWire), with FilterWire non-inferior; only filter devices remain available in the US, and contemporary observational data are conflicting. Where feasible, PCI of the native vessel is preferred over a severely degenerated SVG (Class 2a).[2][16]

Management of No-Reflow

When no-reflow occurs despite a mechanically optimized epicardial vessel, intracoronary vasodilators are the cornerstone (Class 2a, LOE B).[17] Deliver distal to the obstruction via microcatheter for efficacy and to limit systemic hypotension.[18]

Intracoronary agents for no-reflow
Agent Intracoronary dose Notes
Adenosine 100–200 mcg bolus, repeatable Short half-life; transient AV block; caution in asthma
Verapamil up to 200 mcg Avoid in severe LV dysfunction/advanced AV block; useful if spasm-mediated
Nicardipine up to 200 mcg Effective CCB alternative; monitor for hypotension
Nitroprusside 50–300 mcg bolus (max ~1000 mcg) Potent; monitor BP
Epinephrine 20–200 mcg First-line when hypotensive/shock
Nitroglycerin — Ineffective for no-reflow; may worsen hypotension

A network meta-analysis found adenosine, verapamil, epinephrine, and nitroprusside all active without a consistently superior agent.[19][20]

Clinically Actionable Summary

  1. Do not perform routine aspiration thrombectomy in STEMI (Class 3, No Benefit).[2][1]
  2. Optimize upstream/procedural antiplatelet and anticoagulant therapy; consider direct stenting when the lesion crosses easily.
  3. Reserve GP IIb/IIIa inhibitors for large thrombus burden, slow-flow, or no-reflow (Class 2a).[1]
  4. Use bailout aspiration for large residual thrombus after vessel opening or with no-reflow.[3]
  5. Use embolic protection in SVG PCI when feasible (Class 2a).[2]
  6. Treat no-reflow promptly with distally delivered intracoronary vasodilators (Class 2a).[17]

High-Yield Clinical Pearls

  • The stroke hazard from thrombectomy appears within 48 h and includes both ischemic and hemorrhagic strokes—a procedural embolic mechanism.[5]
  • Deliver vasodilators distal to the obstruction via microcatheter; guide-catheter injection is less effective and more hypotensive.[18]
  • Nitroglycerin does not treat no-reflow—reach for adenosine, nitroprusside, nicardipine/verapamil, or epinephrine if hypotensive.[20]
  • In SVG intervention, prefer the native vessel if feasible; if treating the graft, use a filter and consider undersized/direct stenting.[21]

Common Pitfalls

  • Reflexively aspirating large thrombus as a first step rather than reserving it for bailout—stroke risk without proven benefit.[1][5]
  • Misattributing spasm or dissection to "thrombus" and escalating antithrombotics instead of giving vasodilators or stenting.
  • Administering nitroglycerin for no-reflow and worsening hypotension without improving perfusion.[20]
  • Giving intracoronary lytic in a late presenter (ischemic time ≥4 h), where it may increase MVO and myocardial hemorrhage.[13]
  • Routine GP IIb/IIIa in ACS/PCI without a specific thrombotic indication—increases bleeding without ischemic benefit (Class 3: Harm).[1]

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Rao SV, O'Donoghue ML, Ruel M; et al. (2025). "2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes". J Am Coll Cardiol. doi:10.1016/j.jacc.2024.11.009.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 Lawton JS, Tamis-Holland JE, Bangalore S; et al. (2022). "2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization". J Am Coll Cardiol. 79 (2): e21–e129. doi:10.1016/j.jacc.2021.09.006.
  3. ↑ 3.0 3.1 3.2 3.3 Byrne RA, Rossello X, Coughlan JJ; et al. (2023). "2023 ESC Guidelines for the Management of Acute Coronary Syndromes". Eur Heart J. 44 (38): 3720–3826. doi:10.1093/eurheartj/ehad191.
  4. ↑ 4.0 4.1 Jolly SS, James S, Džavík V; et al. (2017). "Thrombus Aspiration in ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis". Circulation. 135 (2): 143–152. doi:10.1161/CIRCULATIONAHA.116.025371. PMID 27941066.
  5. ↑ 5.0 5.1 5.2 Jolly SS, Cairns JA, Yusuf S; et al. (2015). "Stroke in the TOTAL Trial". Eur Heart J. 36 (35): 2364–72. doi:10.1093/eurheartj/ehv296. PMID 26129947.
  6. ↑ Jolly SS, Cairns JA, Yusuf S; et al. (2016). "Outcomes After Thrombus Aspiration for ST Elevation Myocardial Infarction: 1-Year Follow-Up of the TOTAL Trial". Lancet. 387 (10014): 127–35. doi:10.1016/S0140-6736(15)00448-1. PMID 26474811.
  7. ↑ Jolly SS, Cairns JA, Lavi S; et al. (2018). "Thrombus Aspiration in Patients With High Thrombus Burden in the TOTAL Trial". J Am Coll Cardiol. 72 (14): 1589–1596. doi:10.1016/j.jacc.2018.07.047.
  8. ↑ 8.0 8.1 Kelbæk H, Høfsten DE, Køber L; et al. (2016). "Deferred Versus Conventional Stent Implantation in STEMI (DANAMI 3-Defer)". Lancet. 387 (10034): 2199–206. doi:10.1016/S0140-6736(16)30072-1. PMID 27053444.
  9. ↑ Carrick D, Oldroyd KG, McEntegart M; et al. (2014). "A Randomized Trial of Deferred Stenting Versus Immediate Stenting (DEFER-STEMI)". J Am Coll Cardiol. 63 (20): 2088–2098. doi:10.1016/j.jacc.2014.02.530. PMID 24583295.
  10. ↑ Lønborg J, Engstrøm T, Ahtarovski KA; et al. (2017). "Myocardial Damage in Patients With Deferred Stenting After STEMI: A DANAMI-3-DEFER Substudy". J Am Coll Cardiol. 69 (23): 2794–2804. doi:10.1016/j.jacc.2017.03.601. PMID 28595696.
  11. ↑ Mahmoud AN, Saad M, Elgendy AY, Mentias A, Elgendy IY (2018). "Deferred or immediate stent implantation for primary PCI: A meta-analysis". Catheter Cardiovasc Interv. 91 (2): 260–264. doi:10.1002/ccd.27240. PMID 28843018.
  12. ↑ McCartney PJ, Eteiba H, Maznyczka AM; et al. (2019). "Effect of Low-Dose Intracoronary Alteplase During Primary PCI on Microvascular Obstruction". JAMA. 321 (1): 56–68. doi:10.1001/jama.2018.19802. PMID 30620371.
  13. ↑ 13.0 13.1 McCartney PJ, Maznyczka AM, Eteiba H; et al. (2020). "Low-Dose Alteplase During Primary PCI According to Ischemic Time". J Am Coll Cardiol. 75 (12): 1406–1421. doi:10.1016/j.jacc.2020.01.041. PMID 32216908 Check |pmid= value (help).
  14. ↑ Mehta SR, Pinilla-Echeverri N, Tiong D; et al. (2026). "Intracoronary Low-Dose Recombinant Tissue Plasminogen Activator in Primary PCI for STEMI and Large Thrombus Burden: A Randomized Trial (STRIVE)". J Am Coll Cardiol. 87 (3): 238–248. doi:10.1016/j.jacc.2025.10.008.
  15. ↑ Ang SP, Patel D, Chia JE, Lee KS, Shanmugasundaram M (2026). "Intracoronary Thrombolysis During Primary PCI for STEMI: An Updated Meta-Analysis of Randomized-Controlled Trials". Am J Cardiol. doi:10.1016/j.amjcard.2026.06.007. PMID 42264286 Check |pmid= value (help).
  16. ↑ Shoaib A, Kinnaird T, Curzen N; et al. (2019). "Outcomes Following PCI in SVG With and Without Embolic Protection Devices". JACC Cardiovasc Interv. 12 (22): 2286–2295. doi:10.1016/j.jcin.2019.08.037. PMID 31753299.
  17. ↑ 17.0 17.1 Levine GN, Bates ER, Blankenship JC; et al. (2013). "2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention". Catheter Cardiovasc Interv. 82 (4): E266–355. doi:10.1002/ccd.23390. PMID 23299937.
  18. ↑ 18.0 18.1 Rezkalla SH, Stankowski RV, Hanna J, Kloner RA (2017). "Management of No-Reflow Phenomenon in the Catheterization Laboratory". JACC Cardiovasc Interv. 10 (3): 215–223. doi:10.1016/j.jcin.2016.11.059. PMID 28183461.
  19. ↑ Oliveri F, Tua L, Raone L; et al. (2026). "Intracoronary Vasoactive Therapy for No-Reflow During Primary PCI: A Network Meta-Analysis". JACC Adv. 5 (3): 102599. doi:10.1016/j.jacadv.2026.102599.
  20. ↑ 20.0 20.1 20.2 Khialani B, Sim E, Touma G; et al. (2026). "Coronary Slow Flow and No-Reflow During PCI: Imaging-Guided Prediction, Prevention, and Management". Catheter Cardiovasc Interv. 107 (4): 1198–1205. doi:10.1002/ccd.70468.
  21. ↑ Riley RF, Henry TD, Mahmud E; et al. (2020). "SCAI Position Statement on Optimal PCI for Complex Coronary Artery Disease". Catheter Cardiovasc Interv. 96 (2): 346–362. doi:10.1002/ccd.28994. PMID 32406991 Check |pmid= value (help).
Retrieved from "https://www.wikidoc.org/index.php?title=Management_of_the_thrombotic_lesion&oldid=1745749"